Program

Gynecologic Cancers Program

The mission of the Gynecologic Cancers Program is to improve patient outcomes by developing novel strategies for early detection, therapy, and prevention through integrated translational research across the consortium.

The Program encompasses investigation of all Gynecologic cancers including ovarian, endometrial, cervical, vaginal, vulvar, and germ cell cancers as well as gestational trophoblastic disease.

Recent, High-Impact Publications

Defective microhomology-mediated end joining in -deficient tumors.
Zhu G, Asada S, Nguyen H, Hirohashi Y, Sun L, Saravanapavan A, Rahmani E, Hrynashka M, Mukkavalli S, Batish M, Shapiro GI, D'Andrea AD
Science Advances 2026; 12(33):eaed7743.PubMed(opens in new window)
PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.
Hao J, Kochupurakkal B, Branigan TB, Somuncu OS, Liu R, Jadhav H, da Costa AAB, Jiao Y, Yu JZ, Martignetti DB, Sadatrezaei G, Mukkavalli S, Gokhale PC, Cheng SC, Skates SJ, Nasioudis D, Konstantinopoulos PA, Liu JF, Gaillard SL, Giuntoli Ii RL, Martin LP, Tanyi JL, Latif N, Heller IS, Simpkins F, Parmar K, D'Andrea AD, Shapiro GI
The Journal of clinical investigation 2026.PubMed(opens in new window)
Contrasting temporal dynamics of fluorescence and photoacoustic signals from Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors.
Saad MA, Allen D, Sweeney A, Xavierselvan M, Mallidi S, Hasan T
Science Advances 2026; 12(19):eadv4639.PubMed(opens in new window)
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.
Cheng X, Zhang Y, Qian C, Holdridge E, Ananda G, Jiang T, Ni J, Xie S, Gu H, Ji R, Ivanova EV, Nucci MR, Wang Z, Chen K, Kochupurakkal B, Freeman GJ, Shapiro GI, Liu J, Konstantinopoulos PA, Matulonis U, Zhao JJ
Nature Communications 2026.PubMed(opens in new window)
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Konstantinopoulos PA, Zhou N, Penson RT, Le TV, Campos S, Krasner C, Wright AA, Porter R, Horowitz N, Bouberhan S, Liu JF, Hindenach S, Sawyer H, Koppermann L, Hayes M, Polak M, Shea M, Widick P, Cheng SC, Castro C, Beumer JH, Matulonis UA, Lee EK
Nature Communications 2025.PubMed(opens in new window)
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without Mutation.
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; JCO2500225.PubMed(opens in new window)
Neoadjuvant Chemotherapy, Case Volume, and Mortality in Advanced Ovarian Cancer.
Abel MK, Mazina V, Bregar AJ, Gockley AA, Del Carmen MG, Eisenhauer EL, Wilke RN, Rauh-Hain JA, Dottino JA, Melamed A
Jama Network Open 2025; 8(7):e2523434.PubMed(opens in new window)
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.
Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, Nevadunsky NS, Lheureux S, Gaba L, González Cortijo L, Salutari V, You B, Chiang S, O'Connor MJ, Oplustil O'Connor L, Meulendijks D, Khatun M, Ghiorghiu D, Oaknin A
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; JCO2401606.PubMed(opens in new window)